19 October-1 December 2020
The 51st Union World Conference On Lung Health
REGISTER NOW

Sessions

All Sessions
keyboard_arrow_down
keyboard_arrow_down Show filters keyboard_arrow_up Hide filters
  • All Tracks
  • Community Connect
  • Channel 1
  • Channel 2
  • Channel 3
  • Channel 4
  • Channel 5
  • Channel 6
  • Channel 7
  • E-posters
  • Workshops
Channel 6
OA-27-The social impact of TB in Europe
event_note
Loading...
query_builder 12:30 - 13:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-27-The social impact of TB in Europe
*Please scroll down for more information*


12:30 - 12:35: Introduction


12:35 - 12:43: OA-27-667-23-Social risk factors for TB in England: a national point prevalence study 2019 A national point prevalence study in England identified that 25% of the study population had a wide range of social problems relevant to their tuberculosis diagnosis, higher than the 15% who reported to have problems with alcohol and drug misuse, homelessness and imprisonment.

Anjana Roy

12:43 - 12:51: OA-27-668-23-Country-specific approaches and effectiveness of latent TB screening targeting migrants to Europe Migrants in Europe are at an increased risk of active tuberculosis (TB) through reactivation of latent TB infection (LTBI). We did a systematic review and meta-analysis, as well as a survey of TB experts, in 32 European Union/European Economic Area countries and Switzerland, to explore current LTBI screening approaches among recently arrived migrants and the treatment outcomes.

Ioana Margineanu

12:51 - 12:59: OA-27-669-23-High TB and latent TB infection prevalence among minor Eritrean asylum seekers in the Netherlands: importance of travel history The tuberculosis (TB) prevalence rate among unaccompanied minor asylum seekers (UMAs) from Eritrea, who were travelling via Lybia to the Netherlands in 2018, was huge (8,526 per 100,000). In this presentation we show the results of our efforts to test the UMAs without TB for latent TB infection.

Bert A. Wolters

12:59 - 13:07: OA-27-670-23-Investigation of TB underreporting in the federal states of Germany Tuberculosis (TB) under-reporting is a major impediment for TB control efforts. We examined under-reporting of TB from 2009-2018 at the subnational level in Germany. We identified differences in under-reporting between federal states and a variation within states over time. These results will allow for targeted improvements in TB reporting.

Neil J, Saad

13:07 - 13:15: OA-27-671-23-Tuberculosis Source Investigation in the Netherlands – is it Effective? WHO recommends tuberculosis (TB) source investigation (SI) for all children identified with TB. SI aims to detect unidentified source patients or co-infected TB patients and prevent further transmission. As there is limited published evidence on the effectiveness of SI, we present the TB yield of SI in the Netherlands.

Ineke Spruijt

13:15 - 13:23: OA-27-672-23-Evaluating TB transmission in a penitentiary system using customised MIRU-VNTR typing Our study focuses on customising reduced loci set of MIRU-VNTR (mycobacterial interspersed repetitive units–variable tandem repeats) typing for the Georgian population and gives an insight on transmission predictors of tuberculosis (TB) in the penitentiary system, representing as one of the main sources of drug-resistant TB in Georgia.

Nino Maghradze

13:23 - 13:50: Q&A


Loading...
E-posters
EP29-The European TB experience
event_note
Loading...
query_builder 10:00 - 11:00 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel E-poster session
mic English
EP29-The European TB experience
*Please scroll down for more information*
All E-posters are accessible via the "E-posters" section of the conference platform until 30 November.

EP29-376-24-Exploring the differences between groups of tTB cases with unknown treatment outcomes in GermanyReporting tuberculosis (TB) treatment outcomes is important to improve its control efforts. We investigated the characteristics of TB patients with unknown treatment outcomes in Germany. We observed important differences between patients, whose treatment outcomes were reported as missing and as unknown, due to transfer of the patient to different jurisdiction area.
Teresa Domaszewska

EP29-377-24-Can future TB cases be predicted in the Netherlands? What you see is what you get!The extent of tuberculosis (TB) data collection in surveillance systems differs by country. In the Netherlands, data is collected on country of birth and duration of stay/residence of foreign-born patients. This study presents trends for different sub-groups i.e. patients born in the Netherlands and foreign-born patients, by time, in the Netherlands.
Gerard De Vries

EP29-378-24-TB healthcare-seeking among contacts of active TB patients: evaluation of symptom screening in a nationwide contact investigation in the country of GeorgiaWe conducted a cohort study among contacts of patients with tuberculosis (TB) from Georgia. Contacts received TB symptom screening and were referred to care. Less than half of contacts with symptoms received diagnostic testing for active TB and TB incidence was almost seven times higher among symptomatic contacts, compared to asymptomatic contacts.
Ana Giguashvili

EP29-379-24-Molecular characterisation of Mycobacterium tuberculosis isolates in the Russian region with unexpectedly low TB incidenceThe Vologda region is located in the north of the European part of Russia and is characterised by an unexpectedly low tuberculosis (TB) incidence rate of 15.8 /100,000 (Russian average - 44.4). This situation is intriguing and we analysed Mycobacterium tuberculosis population structure to understand the likely underlying, pathogen related factors.
Anna Vyazovaya

EP29-380-24-Treatment of rifampin-resistant TB with an all-oral regimen containing new drugs in Zhytomyr UkraineUkraine is a country with high burden rifampin-resistant and multidrug-resistant forms of tuberculosis (RR/MDR-TB) and poor treatment success rates. We assess the effectiveness, safety and tolerability of an all-oral, nine-12 month regimen, containing bedaquiline with levofloxacin or delamanid, for the treatment of RR/MDR-TB in Zhytomyr, Ukraine.
Chung-Yu Chen

EP29-381-24-Implementation and acceptance of video consultation in the treatment and care of drug-sensitiveTB and latent TB infection in The NetherlandsNurses who are specialised in tuberculosis (TB) management, counsel patients with latent TB infection during their treatment. eHealth, in the form of video consultation, has the potential to support counselling. This study focused on the acceptance of video consultation, both by patients and nurses, and aimed to provide guidance for nurses considering video consultation.
Simone Boerema

EP29-382-24-A European TB strategy toolkit: supporting the development and strengthening of national TB programmes in the European Union and European Economic Area Member StatesA European TB strategy toolkit, commissioned by the European Commission and supported by the European Centre for Disease Prevention and Control, and World Health Organization Europe, has been developed. It supports prioritisation of areas for action and equips Member States with underpinning European Union/European Economic Area-focused evidence in developing national strategic TB plans to move countries, and Europe, toward TB elimination. 
Fatima Wurie

EP29-383-24-The use of totally implantable central venous access ports system for the treatment of multidrug-resistant TB: Belarus prospective cohort studyTotally implantable, central venous access port system (CVP) helps to provide multidrug-resistant tuberculosis treatment with carbapenem- containing regimens. Following a pilot project (supported by Médecins Sans Frontières) CVP use was programmatically expanded with Global Fund support. In a countrywide cohort, CVP demonstrates a good safety profile and a high level of patient acceptability.
Aliaksandr Skrahin

Loading...
Processing. Please wait.
Loading...